

Title	One Year of Preemptive Valganciclovir Administration in Children After Liver Transplantation
Author(s)	Ueno, Takehisa; Kodama, Tasuku; Noguchi, Yuki et al.
Citation	Transplantation Proceedings. 2020, 52(6), p. 1852-1854
Version Type	AM
URL	https://hdl.handle.net/11094/96478
rights	© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
Note	

Osaka University Knowledge Archive : OUKA

<https://ir.library.osaka-u.ac.jp/>

Osaka University

	One-year (n=32)	< One-year (n=24)	<i>p</i> =
Mean age at transplant	3.9 years	4.6 years	0.55
Sex (Female:male)	18:14	16:8	0.43
Original disease (BA:other)	29:13	16:8	0.22
Steroid expose (Mean±SD)	12±0 months	5.6±2.7 months	<0.001
VGCV (Mean±SD)	12±0 months	4.5±1.5 months	<0.001
Viral status			
CMV infection	6.5%	33.3%	0.008
EBV seronegative	55% (R- n=20)	36%(R- n=14)	0.17

Table 1 Patient demographic and viral status: No deference of age, sex original disease between two groups. < One-year group had shorter steroid dose. A rate of EBV seronegative during observation period was a rate out of pre-transplant EBV negative recipient in each group. VGCV: valganciclovir; CMV: cytomegalovirus; EBV: Epstein - Barr virus